EMERGING BIOELECTRONIC MEDICINE & NEUROSTIMULATION TECHNOLOGIES: GROWING AND DISRUPTING GLOBAL MEDICAL DEVICE MARKETS

300 Pages | 55 Exhibits | 2018 Analysis | Forecasts Through 2023

OVERVIEW:
The global neurostimulation market is projected to increase 13.4% annually from 2017 through 2022 to more than $7.2 billion. Although impressive, this growth will understate the magnitude of the patient populations and clinical applications that will be newly served with the emergence of noninvasive alternatives to expensive neurostimulation implants and the development of new forms of stimulation that will enable less invasive treatment of chronic conditions. It is significant that many of the largest patient populations with chronic conditions are currently treated with drugs, which are marginally successful and frequently have undesirable side effects. New device-based therapies are delivering superior outcomes with virtually no side effects at a reasonable cost. They are also more patient-friendly. Although some of these technologies will emerge only after 2020, biomedical electronic medicine's focus on the vagus nerve as the "neural highway" for selectively reactivating the body's native homeostasis mechanism, coupled with continued major developments in neurostimulation tools and techniques, will ensure a sustained pipeline of device-based alternatives to drug therapy and invasive treatments through the next decades.

These are among the findings of Health Research International's new report entitled "Emerging Bioelectronic Medicine and Neurostimulation Technologies: Growing and Disrupting Global Medical Device Markets". This 300-page report encompasses nearly 60 tables and exhibits and profiles 74 companies innovating technologies that are helping to drive the development of this new paradigm in medicine. Covered clinical applications include drug-refractory epilepsy, migraine and cluster headache, major depressive disorder, Parkinson's, Essential Tremor, Alzheimer's, autism, opioid withdrawal, psychiatric disorders, hemorrhage, rheumatoid arthritis, Crohn's, post-stroke mobility, chronic pain, heart failure, incontinence, sleep apnea, hearing disorders, respiratory insufficiency and gastroesophageal reflux disease. The report incorporates global models for each clinical application and sales by application for four major geographies; however, the detailed econometric models used to build each global market are available in Excel spreadsheets for purchase separately. Contact Life Science Intelligence, the exclusive distributor for HRI reports, for a complete Table of Contents and List of Exhibits of this "must have" report.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

1.0 BACKGROUND ON BIOELECTRONIC MEDICINE & NEUROSTIMULATION
	
1.1 The Beginning: Cardiac Rhythm Management	
	1.1.1 Pacemakers: Overwriting Abnormal Electrical Activity of the Heart	
	1.1.2 High Power CRM Devices	
	1.1.3 External CRM Devices:  Saving Lives Outside of Hospitals	
	1.1.4 Arrhythmia Ablation: Isolating Parasitic Conduction Pathways	
1.2 Expanding Technologies & Applications: Neuromodulation	
	1.2.1 Spinal Cord Stimulation	
	1.2.2 Deep Brain Stimulation	
	1.2.3 Sacral Nerve Modulation	
	1.2.4 Vagus Nerve Stimulation	
	1.2.5 New and Emerging Neurostimulation Targets	

Exhibit 1-1: Overview of Cardiac Rhythm Management (CRM) Products	
Exhibit 1-2: Overview of Selected Neurostimulation Technologies and Applications

2.0 VAGUS NERVE AND NATIVE HOMEOSTASIS MECHANISM
	
2.1 Overview of Native Homeostasis Mechanism	
	2.1.1 Parameters Monitored	
		2.1.1.1 Core Temperature	
		2.1.1.2 Blood Glucose	
		2.1.1.3 Blood Calcium, Sodium, Potassium and Iron	
		2.1.1.4 Blood Oxygen, CO2 Saturation, pH	
		2.1.1.5 Arterial Blood Pressure, Heart Rate, Respiration	
	2.1.2 Homeostatic Failures	
2.2 Main Components of Homeostasis Mechanism	
	2.2.1 Cell Signaling	
		2.2.1.1 Neurotransmitters	
		2.2.1.2 Cell Receptors	
	2.2.2 Endocrinal Signaling Features	
		2.2.2.1 Hormones	
		2.2.2.2 Cytokines and Other Components	
2.3 Vagus Nerve Functional Anatomy and Role in Homeostasis Processes	
	2.3.1 Functional Anatomy	
	2.3.2 Role in Homeostasis Process	
2.4 Challenges and Limitations	

Exhibit 2-1: Schematic of Basic Native Homeostasis System	
Exhibit 2-2: Key Parameters Monitored by Homeostasis Mechanism	
Exhibit 2-3: Major Components of Homeostasis Mechanism	
Exhibit 2-4: Anatomy of a Neuron	
Exhibit 2-5: Schematic of Signaling Process	
Exhibit 2-6: Components, Functions, and Peripheral Distribution of Vagus Nerve Fibers

3.0 NEUROSTIMULATION TARGETED CLINICAL APPLICATIONS
	
3.1 Inflammatory Conditions	
	3.1.1 Rheumatoid Arthritis	
	3.1.2 Inflammatory Bowel Disease	
	3.1.3 Multiple Sclerosis	
3.2 Neurological Diseases	
	3.2.1 Refractory Epilepsy	
	3.2.2 Cluster Headaches	
	3.2.3 Migraine	
	3.2.4 Chronic Depression	
	3.2.5 Post-Traumatic Stress Disorder	
	3.2.6 Ischemic Stroke	
	3.2.7 Neurodegenerative Disorders	
		3.2.7.1 Parkinson's Disease	
		3.2.7.2 Essential Tremor	
		3.2.7.3 Alzheimers	
		3.2.7.4 Amyotrophic Lateral Sclerosis (ALS)	
3.3 Hematologic Conditions	
	3.3.1 Postpartum Hemorrhage	
	3.3.2 Hemophilia	
3.4 Metabolic Conditions	
	3.4.1 Obesity	
	3.4.2 Type 2 Diabetes	
3.5 Cardiology Conditions: Heart Failure	
3.6 Sleep Apnea	
	3.6.1 Obstructive Sleep Apnea (OSA)	
	3.6.2 Central Sleep Apnea (CSA)	
3.7 Urological Conditions	
	3.7.1 Urinary Incontinence	
	3.7.2 Overactive Bladder (OAB)	
3.8 Other Targeted Applications	

Exhibit 3-1: Overview of Selected Inflammatory Conditions Potentially Amenable to VNS Therapy             
Exhibit 3-2: Incidence of Inflammatory Bowel Disease for Selected Nations                    
Exhibit 3-3: Prevalence of Inflammatory Bowel Disease by Geography, 2015                  
Exhibit 3-4: Global Distribution of Multiple Sclerosis, 2017                                              
Exhibit 3-5: Overview of Selected Neurological Conditions Potentially Amenable to Neurostimulation Therapy  
Exhibit 3-6: Distribution of Depression by Geography, Age and Sex, 2015                      
Exhibit 3-7: Current and Forecast Prevalence of Alzheimer's, 2015-2050                        
Exhibit 3-8: Growth in Prevalence of Amyotrophic Lateral Sclerosis, 2015 - 2040         
Exhibit 3-9: Overview of Selected Hematologic Conditions Potentially Amenable to Neurostimulation Therapy   
Exhibit 3-10: Overview of Selected Metabolic Conditions Potentially Amenable to Neurostimulation Therapy    
Exhibit 3-11: Adult Obesity as Share of Population, 2012 or Most Recent Year               
Exhibit 3-12: Global Population 20-79 with Diabetes, 2017 and 2045                                
Exhibit 3-13: Overview of Heart Failure                                                                     
Exhibit 3-14: Overview of Sleep Apnea Potentially Amenable to Neurostimulation Therapy                      
Exhibit 3-15: Overview of Urological Conditions Potentially Amenable to Neurostimulation Therapy            
Exhibit 3-16: Other Clinical Applications Potentially Amenable to Neurostimulation Therapy                                                                          

4.0 PRODUCTS AND TECHNOLOGIES
	
4.1 Neurological Conditions	
	4.1.1 Drug Refractory Epilepsy	
		4.1.1.1 Bionic Enterprises	
		4.1.1.2 Cerbomed	
		4.1.1.3 CerebralRX	
		4.1.1.4 LivaNova	
		4.1.1.5 NeuroPace	
		4.1.1.6 NeuroSigma	
		4.1.1.7 PINS Medical	
	4.1.2 Drug Resistant Depression	
		4.1.2.1 BrainsWay	
		4.1.2.2 Cerbomed	
		4.1.2.3 Cervel Neurotech/Rio Grande Neurosciences	
		4.1.2.4 CerebralRx	
		4.1.2.5 LivaNova	
		4.1.2.6 MagVenture	
		4.1.2.7 Neuronetics	
		4.1.2.8 Tal Medical	
	4.1.3 Migraine/Cluster Headache	
		4.1.3.1 Automomic Technologies	
		4.1.3.2 Cephaly Technology	
		4.1.3.3 Cerbomed	
		4.1.3.4 electroCore	
		4.1.3.5 eNeura	
		4.1.3.6 Scion NeuroStim	
	4.1.4 Neurodegenerative Disorders	
		4.1.4.1 Aleva Neurotherapeutics	
		4.1.4.2 Bioinduction	
		4.1.4.3 Functional Neuromodulation	
		4.1.4.4 Neuronix	
	4.1.5 Stroke, Spinal Cord Injury and Limb Loss	
		4.1.5.1 Bioness	
		4.1.5.2 Finetech Medical	
		4.1.5.3 MicroTransponder	
		4.1.5.4 Ottobock	
		4.1.5.5 Massachusetts General Hospital	
		4.1.5.6 Sheffield Teaching Hospital	
4.2 Chronic Pain (ex Headache)	
	4.2.1 BioElectronic Corporation	
	4.2.2 BlueWind Medical	
	4.2.3 Cerbomed	
	4.2.4 Mainstay Medical	
	4.2.5 NeuroMetrix	
	4.2.6 Nevro	
	4.2.7 Saluda Medical	
	4.2.8 SPR Therapeutics	
	4.2.9 Stimwave	
4.3 Autoimmune Inflammatory Conditions	
	4.3.1 Rheumatoid Arthritis	
	4.3.2 Crohn's Disease	
4.4 Hematologic Disorders: Sanguistat	
4.5 Metabolic Disorders: Obesity	
	4.5.1 University of Saint Etienne Medical Center	
	4.5.2 Federal University of Sao Paulo	
4.6 Cardiovascular Disorders: Heart Failure	
	4.6.1 BioControl Medical	
	4.6.2 Cardionomic	
	4.6.3 CVRx	
	4.6.4 Enopace Medical	
	4.6.5 Impulse Dynamics	
	4.6.6 LivaNova	
	4.6.7 Oklahoma State University Health Sciences Center	
4.7 Urologic Disorders	
	4.7.1 Axonics Modulation Technologies	
	4.7.2 BlueWind Medical	
	4.7.3 Cogentix Medical	
	4.7.4 FemPulse LLC	
4.8 Sleep Disorders	
	4.8.1 Inspire Medical	
	4.8.2 LivaNova/ImThera Medical	
	4.8.3 Respicardia	
4.9 Hearing Disorders: Chronic Tinnitus	
	4.9.1 CorTec/Wyss Center	
	4.9.2 MicroTransponder	
4.10 Gastrointestinal Disorders: GERD	
4.11 Breathing Disorders: Respiratory Insufficiency	
4.12 Opioid Withdrawal Symptoms	
4.13 Autism	

Exhibit 4-1: Current & Emerging Bioelectronic Medicine and Neurostimulation By Clinical Application 
                                                                                   
5.0 MARKETS BY APPROACH AND CLINICAL APPLICATION
	
5.1 Neurological Disorders	
	5.1.1 Parkinson's/Essential Tremor/Alzheimer's (Deep Brain Stimulation)	
	5.1.2 Drug-Refractory Epilepsy	
	5.1.3 Major Depressive Disorder	
	5.1.4 Migraine/Cluster Headache	
	5.1.5 Post-Stroke Mobility	
5.2 Hematologic Disorders (PostPartum Hemorrhage)	
5.3 AutoImmune Inflammatory Disorders	
5.4 Chronic Widespread Pain	
5.5 Cardiovascular Disorders (Heart Failure)	
5.6 Incontinence	
5.7 Sleep Apnea	
5.8 Breathing Disorders (Respiratory Insufficiency)	
5.9 Other Disorders	

Exhibit 5-1: Global Markets by Approach and Clinical Application, 2016-2022	
Exhibit 5-2: Global Market for Technologies Targeting Neurological Disorders, 2016-2022	
Exhibit 5-3: Global Market for Deep Brain Stimulation Technologies by Approach, 2016-2022	
Exhibit 5-4: Global Deep Brain Stimulation Market, Estimated Supplier Shares, 2017	
Exhibit 5-5: Global Market for Technologies Targeting Drug-Refractory Epilepsy by Approach, 2016-2022	
Exhibit 5-6: Global Drug Refractory Epilepsy Neurostimulation Devices Market, Estimated Supplier Shares, 2017	
Exhibit 5-7: Global Market for Neurostimulation Technologies Targeting Major Depressive Disorder by Approach, 2016-2022	
Exhibit 5-8: Global Major Depressive Disorder Neurostimulation Devices Market, Estimated Supplier Shares, 2017	
Exhibit 5-9: Global Market for Neurostimulation Technologies Targeting Migraine and Cluster Headache, 2016-2022	
Exhibit 5-10: Global Migraine/Cluster Headache VNS Therapies Market, Estimated Supplier Shares, 2017	
Exhibit 5-11: Global Market for Neurostimulation Technologies Targeting Post-Stroke Mobility by Approach, 2016-2022	
Exhibit 5-12: Global Post-Stroke Mobility Neurostimulation Therapy Devices Market, Estimated Supplier Shares, 2017	
Exhibit 5-13: Global Market for Neurostimulation Technologies Targeting Hematological Disorders, 2016-2022	
Exhibit 5-14: Global Market for Neurostimulation Technologies Targeting Autoimmune Disorders, 2016-2022	
Exhibit 5-15: Global Market for Neurostimulation Technologies Targeting Chronic Pain by Approach, 2016-2022	
Exhibit 5-16: Global Chronic Pain Neurostimulation Devices Market, Estimated Supplier Shares, 2017
Exhibit 5-17: Global Market for Neurostimulation Technologies Targeting Heart Failure, 2016-2022	
Exhibit 5-18: Global Heart Failure Neurostimulation Devices Market, Estimated Supplier Shares, 2017	
Exhibit 5-19: Global Market for Neurostimulation Technologies Targeting Incontinence by Approach, 2016-2022	
Exhibit 5-20: Global Incontinence Neurostimulation Devices Market, Estimated Supplier Shares, 2017	
Exhibit 5-21: Global Market for Neurostimulation Technologies Targeting Sleep Apnea, 2016-2022	
Exhibit 5-22: Global Sleep Apnea Neurostimulation Market, Estimated Supplier Shares, 2017	
Exhibit 5-23: Global Market for Neurostimulation Technologies Targeting Respiratory Insufficiency, 2016-2022	
Exhibit 5-24: Global Respiratory Insufficiency Neurostimulation Devices Market, Estimated Supplier Shares, 2017	
Exhibit 5-25: Global Market for Other Neurostimulation Technologies, 2016-2022

6.0 MARKETS BY MAJOR GEOGRAPHY
	
6.1 United States	
6.2 Major Europe	
6.3 Major Asia	
6.4 Rest of World	

Exhibit 6-1: Global Market for Neurostimulation Technologies by Major Geography, 2016-2022	
Exhibit 6-2: U.S. Market for Neurostimulation Technologies by Clinical Application, 2016-2022
Exhibit 6-3: Major Europe Market for Neurostimulation Technologies by Clinical Application, 2016-2022	
Exhibit 6-4: Major Asia Market for Neurostimulation Technologies by Clinical Application, 2016-2022	
Exhibit 6-5: Rest-of-World Market for Neurostimulation Technologies by Clinical Application, 2016-2022

7.0 COMPANY PROFILES
	
7.1 Abbott Laboratories (St. Jude Medical)	
7.2 Aleva Neurotherapeutics	
7.3 Alfred Mann Foundation	
7.4 Atrotech Oy	
7.5 Autonomic Technologies	
7.6 Avery Biomedical	
7.7 Axonics Modulation Technologies	
7.8 BioControl Medical	
7.9 BioElectronics Corporation	
7.10 Bioinduction/Finetech Medical	
7.11 Bioness	
7.12 Bionic Enterprises	
7.13 BlueWind Medical	
7.14 Boston Scientific Corporation	
7.15 BrainsWay	
7.16 Burke Medical Research Institute	
7.17 Cala Health	
7.18 Cardionomic	
7.19 Cephaly Technology (STX-Med)	
7.20 Cerbomed GmbH	
7.21 CerebralRx	
7.22 Clinatec	
7.23 Cogentix Medical	
7.24 CorTec/Wyss Center	
7.25 CVRx	
7.26 Deep Brain Innovations	
7.27 Defense Advanced Research Projects Agency	
7.28 electroCore	
7.29 Endonovo Therapeutics	
7.30 EndoStim	
7.31 eNeura	
7.32 Enopace Medical	
7.33 Feinstein Institute for Medical Research (Northwell Health)	
7.34 FemPulse LLC	
7.35 Functional Neuromodulation	
7.36 Galvani Bioelectronics	
7.37 Hanger	
7.38 Hobart Group (Lavita, MetaCure, Renal Dynamics, Impulse Dynamics)	
7.39 Innovative Health Solutions	
7.40 Inspire Medical Systems	
7.41 IntraPace	
7.42 Laboratoire MXM (Axonic Neuromodulation Systems)	
7.43 LivaNova (Cyberonics, ImThera)	
7.44 MagVenture	
7.45 Mainstay Medical	
7.46 Medtronic	
7.47 Micro Transponder	
7.48 Neurolief	
7.49 NeuroMetrix	
7.50 Neuronetics	
7.51 Neuronix	
7.52 NeuroPace	
7.53 NeuroSigma	
7.54 Neuros Medical	
7.55 NeuroTech International Ltd./AAT Research Ltd.	
7.56 NeuroTronik	
7.57 Nevro	
7.58 Nexeon Medsystems/Nuviant Medical	
7.59 Nuvectra	
7.60 Ottobock	
7.61 (Beijing) PINS Medical	
7.62 ReShape Lifesciences (EnteroMedics)	
7.63 Respicardia	
7.64 Saluda Medical	
7.65 Sanguistat	
7.66 SceneRay	
7.67 Scion NeuroStim	
7.68 SetPoint Medical	
7.69 SPR Therapeutics	
7.70 Stimwave	
7.71 Synapse Biomedical	
7.72 Tal Medical	
7.73 CHUs Jean Monnet &Saint Etienne/Life Medical Control/NBA Techno	
7.74 University of California Berkeley


COMPANIES COVERED:

  1. Abbott Laboratories (St. Jude Medical)
  2. Aleva Neurotherapeutics
  3. Alfred Mann Foundation
  4. Atrotech Oy
  5. Autonomic Technologies
  6. Avery Biomedical
  7. Axonics Modulation Technologies
  8. BioControl Medical
  9. BioElectronics Corporation
  10. Bioinduction/Finetech Medical
  11. Bioness
  12. Bionic Enterprises
  13. BlueWind Medical
  14. Boston Scientific Corporation
  15. BrainsWay
  16. Burke Medical Research Institute
  17. Cala Health
  18. Cardionomic
  19. Cephaly Technology (STX-Med)
  20. Cerbomed GmbH
  21. CerebralRx
  22. Clinatec
  23. Cogentix Medical
  24. CorTec/Wyss Center
  25. CVRx
  26. Deep Brain Innovations
  27. Defense Advanced Research Projects Agency
  28. electroCore
  29. Endonovo Therapeutics
  30. EndoStim
  31. eNeura
  32. Enopace Medical
  33. Feinstein Institute for Medical Research (Northwell Health)
  34. FemPulse LLC
  35. Functional Neuromodulation
  36. Galvani Bioelectronics
  37. Hanger
  38. Hobart Group (Lavita, MetaCure, Renal Dynamics, Impulse Dynamics)
  39. Innovative Health Solutions
  40. Inspire Medical Systems
  41. IntraPace
  42. Laboratoire MXM (Axonic Neuromodulation Systems)
  43. LivaNova (Cyberonics, ImThera)
  44. MagVenture
  45. Mainstay Medical
  46. Medtronic
  47. Micro Transponder
  48. Neurolief
  49. NeuroMetrix
  50. Neuronetics
  51. Neuronix
  52. NeuroPace
  53. NeuroSigma
  54. Neuros Medical
  55. NeuroTech International Ltd./AAT Research Ltd.
  56. NeuroTronik
  57. Nevro
  58. Nexeon Medsystems/Nuviant Medical
  59. Nuvectra
  60. Ottobock
  61. (Beijing) PINS Medical
  62. ReShape Lifesciences (EnteroMedics)
  63. Respicardia
  64. Saluda Medical
  65. Sanguistat
  66. SceneRay
  67. Scion NeuroStim
  68. SetPoint Medical
  69. SPR Therapeutics
  70. Stimwave
  71. Synapse Biomedical
  72. Tal Medical
  73. CHUs Jean Monnet &Saint Etienne/Life Medical Control/NBA Techno
  74. University of California Berkeley
Contact Us

Need help finding medtech research? Let us help you!